Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors.

Nature communications·2026
Same author

Stress-induced proteome remodeling at the Golgi-endosome interface.

Journal of cell science·2026
Same author

Optogenetic stimulation of Lbc GEF-mediated Rho activity dynamics promotes cell invasion.

Molecular biology of the cell·2025
Same author

GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells.

Oncotarget·2025
Same author

pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells.

Frontiers in immunology·2025

Related Experiment Video

Updated: May 15, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

New developments in biomarkers for melanoma.

Klaus G Griewank1, Selma Ugurel, Dirk Schadendorf

  • 1Department of Dermatology, University Hospital Essen, Essen, Germany.

Current Opinion in Oncology
|January 22, 2013
PubMed
Summary

New biomarkers for malignant melanoma are crucial for predicting treatment response. Genetic and immune markers show promise for personalizing melanoma therapy and improving patient outcomes.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Experiment Videos

Last Updated: May 15, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Malignant melanoma treatment has advanced with gene mutation-based therapies and immunotherapies.
  • These treatments improve survival but have limitations, necessitating better biomarkers.
  • Identifying predictive biomarkers is key for optimizing melanoma treatment strategies.

Purpose of the Study:

  • To review recent developments in genetic and immunological biomarkers for malignant melanoma.
  • To highlight their role in predicting treatment response and prognosis.
  • To discuss the future of personalized melanoma therapy.

Main Methods:

  • Review of current literature on melanoma biomarkers.
  • Analysis of genetic alterations (oncogene mutations, epigenetic changes) as biomarkers.
  • Evaluation of immunological markers, including tumor-infiltrating lymphocytes and immune gene signatures.

Main Results:

  • Activating oncogene mutations are significant melanoma biomarkers, predicting response to kinase inhibitors and prognosis.
  • Epigenetic alterations are emerging as valuable biomarkers.
  • Tumor-reactive cytotoxic T cells and combined immune profiling predict prognosis and immunotherapy response.

Conclusions:

  • Genetic melanoma markers are clinically relevant and their importance will grow.
  • Immunological biomarkers are increasingly vital for predicting treatment response.
  • Personalized melanoma therapy will be enhanced by integrating genetic and immunological biomarker data.